Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755 is registered in ClinicalTrials.gov with Asana BioSciences as lead sponsor.

NCT NCT03654755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Asana BioSciences
Phase
Phase 2
Overall status
Terminated
Start date
September 29, 2018
Completion date
October 29, 2019
Enrollment
162 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis